Kamada Ltd (KMDA)

$5.25

+0.05

(+0.96%)▲

Market is closed - opens 7 PM, 14 Oct 2024

Performance

  • $5.20
    $5.25
    $5.25
    downward going graph

    0.95%

    Downside

    Day's Volatility :0.95%

    Upside

    0.0%

    downward going graph
  • $4.08
    $6.53
    $5.25
    downward going graph

    22.29%

    Downside

    52 Weeks Volatility :37.51%

    Upside

    19.59%

    downward going graph

Returns

PeriodKamada Ltd
3 Months
-9.17%
6 Months
2.54%
1 Year
10.29%
3 Years
-0.94%

Highlights

Market Capitalization
301.8M
Book Value
$4.54
Earnings Per Share (EPS)
0.27
PE Ratio
19.44
PEG Ratio
8.75
Wall Street Target Price
14.0
Profit Margin
9.75%
Operating Margin TTM
13.28%
Return On Assets TTM
3.16%
Return On Equity TTM
7.05%
Revenue TTM
154.6M
Revenue Per Share TTM
2.84
Quarterly Revenue Growth YOY
13.4%
Gross Profit TTM
46.7M
EBITDA
28.4M
Diluted Eps TTM
0.27
Quarterly Earnings Growth YOY
1.0
EPS Estimate Current Year
0.26
EPS Estimate Next Year
0.31
EPS Estimate Current Quarter
0.06
EPS Estimate Next Quarter
0.06

Analyst Recommendation

Buy
    85%Buy
    14%Hold
    0
    0%Sell
Based on 7 Wall street analysts offering stock ratings for Kamada Ltd(by analysts ranked 0 to 5 stars)
Based on 7 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
6
6
6
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 166.67%

Current $5.25
Target $14.00

Company Financials

FY18Y/Y Change
Revenue
114.5M
↑ 11.32%
Net Income
22.3M
↑ 223.08%
Net Profit Margin
19.48%
↑ 12.77%
FY19Y/Y Change
Revenue
127.2M
↑ 11.11%
Net Income
22.3M
↓ 0.2%
Net Profit Margin
17.49%
↓ 1.99%
FY20Y/Y Change
Revenue
133.2M
↑ 4.76%
Net Income
17.1M
↓ 22.97%
Net Profit Margin
12.86%
↓ 4.63%
FY21Y/Y Change
Revenue
103.6M
↓ 22.22%
Net Income
-2.2M
↓ 113.01%
Net Profit Margin
-2.15%
↓ 15.01%
FY22Y/Y Change
Revenue
129.3M
↑ 24.79%
Net Income
-2.3M
↑ 4.08%
Net Profit Margin
-1.79%
↑ 0.36%
FY23Y/Y Change
Revenue
144.8M
↑ 11.92%
Net Income
8.3M
↓ 456.92%
Net Profit Margin
5.72%
↑ 7.51%
Q1 FY23Q/Q Change
Revenue
37.4M
↓ 17.6%
Net Income
1.8M
↓ 38.45%
Net Profit Margin
4.84%
↓ 1.64%
Q2 FY23Q/Q Change
Revenue
37.4M
↑ 0.0%
Net Income
1.8M
↑ 0.0%
Net Profit Margin
4.84%
↑ 0.0%
Q3 FY23Q/Q Change
Revenue
37.9M
↑ 1.31%
Net Income
3.2M
↑ 77.87%
Net Profit Margin
8.5%
↑ 3.66%
Q4 FY23Q/Q Change
Revenue
37.4M
↓ 1.41%
Net Income
2.4M
↓ 26.62%
Net Profit Margin
6.32%
↓ 2.18%
Q1 FY24Q/Q Change
Revenue
37.7M
↑ 0.9%
Net Income
2.4M
↑ 0.0%
Net Profit Margin
6.27%
↓ 0.05%
Q2 FY24Q/Q Change
Revenue
41.9M
↑ 10.97%
Net Income
4.4M
↑ 87.15%
Net Profit Margin
10.57%
↑ 4.3%
FY18Y/Y Change
Total Assets
138.1M
↑ 13.11%
Total Liabilities
25.7M
↓ 21.09%
FY19Y/Y Change
Total Assets
173.8M
↑ 25.83%
Total Liabilities
38.5M
↑ 49.49%
FY20Y/Y Change
Total Assets
210.7M
↑ 21.21%
Total Liabilities
32.0M
↓ 16.77%
FY21Y/Y Change
Total Assets
318.7M
↑ 51.27%
Total Liabilities
141.8M
↑ 342.89%
FY22Y/Y Change
Total Assets
322.4M
↑ 1.16%
Total Liabilities
146.4M
↑ 3.18%
FY23Y/Y Change
Total Assets
352.0M
↑ 9.18%
Total Liabilities
110.0M
↓ 24.86%
Q1 FY23Q/Q Change
Total Assets
314.4M
↓ 2.48%
Total Liabilities
137.6M
↓ 5.96%
Q2 FY23Q/Q Change
Total Assets
314.4M
↑ 0.0%
Total Liabilities
137.6M
↑ 0.0%
Q3 FY23Q/Q Change
Total Assets
337.1M
↑ 7.21%
Total Liabilities
98.7M
↓ 28.31%
Q4 FY23Q/Q Change
Total Assets
340.1M
↑ 0.89%
Total Liabilities
95.8M
↓ 2.92%
Q1 FY24Q/Q Change
Total Assets
343.2M
↑ 0.92%
Total Liabilities
96.7M
↑ 0.92%
Q2 FY24Q/Q Change
Total Assets
349.9M
↑ 1.97%
Total Liabilities
99.6M
↑ 3.01%
FY18Y/Y Change
Operating Cash Flow
10.5M
↑ 171.11%
Investing Cash Flow
-5.2M
↓ 66.84%
Financing Cash Flow
-587.0K
↓ 103.83%
FY19Y/Y Change
Operating Cash Flow
27.6M
↑ 161.44%
Investing Cash Flow
-564.0K
↓ 89.1%
Financing Cash Flow
-1.5M
↑ 160.65%
FY20Y/Y Change
Operating Cash Flow
19.1M
↓ 30.71%
Investing Cash Flow
-13.1M
↑ 2227.48%
Financing Cash Flow
23.4M
↓ 1627.06%
FY21Y/Y Change
Operating Cash Flow
-8.8M
↓ 146.16%
Investing Cash Flow
-61.1M
↑ 365.07%
Financing Cash Flow
18.6M
↓ 20.42%
FY22Y/Y Change
Operating Cash Flow
28.6M
↓ 424.14%
Investing Cash Flow
-3.8M
↓ 93.8%
Financing Cash Flow
-9.3M
↓ 150.25%
Q1 FY23Q/Q Change
Operating Cash Flow
1.8M
↓ 73.03%
Investing Cash Flow
-1.1M
↑ 9.57%
Financing Cash Flow
-5.9M
↑ 103.86%
Q2 FY23Q/Q Change
Operating Cash Flow
1.8M
↑ 0.0%
Investing Cash Flow
-1.0M
↓ 2.1%
Financing Cash Flow
-5.9M
↑ 0.0%
Q3 FY23Q/Q Change
Operating Cash Flow
921.0K
↓ 49.34%
Investing Cash Flow
-1.7M
↑ 64.98%
Financing Cash Flow
31.3M
↓ 634.5%

Technicals Summary

Sell

Neutral

Buy

Kamada Ltd is currently in a neutral trading position according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Kamada Ltd
Kamada Ltd
-3.85%
2.54%
10.29%
-0.94%
3.96%
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
-5.53%
-12.33%
2.35%
11.42%
27.02%
Haleon Plc Spon Ads
Haleon Plc Spon Ads
-4.38%
24.69%
23.92%
35.63%
35.63%
Zoetis Inc.
Zoetis Inc.
-0.53%
26.91%
9.0%
-3.74%
50.15%
Viatris Inc.
Viatris Inc.
-2.4%
0.53%
21.97%
-14.88%
-30.35%
Catalent, Inc.
Catalent, Inc.
1.39%
7.79%
30.28%
-52.83%
25.05%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Kamada Ltd
Kamada Ltd
19.44
19.44
8.75
0.26
0.07
0.03
NA
4.54
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
34.89
34.89
0.26
4.57
0.16
0.12
NA
24.87
Haleon Plc Spon Ads
Haleon Plc Spon Ads
32.65
32.65
1.5
0.39
0.07
0.04
0.02
1.82
Zoetis Inc.
Zoetis Inc.
37.29
37.29
2.59
5.82
0.49
0.14
0.01
10.94
Viatris Inc.
Viatris Inc.
224.4
NA
0.07
2.67
-0.03
0.03
0.04
16.36
Catalent, Inc.
Catalent, Inc.
211.02
NA
2.89
0.2
-0.25
0.0
NA
19.91
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Kamada Ltd
Kamada Ltd
Buy
$301.8M
3.96%
19.44
9.75%
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
Buy
$11.7B
27.02%
34.89
16.0%
Haleon Plc Spon Ads
Haleon Plc Spon Ads
Buy
$45.8B
35.63%
32.65
9.66%
Zoetis Inc.
Zoetis Inc.
Buy
$86.2B
50.15%
37.29
26.29%
Viatris Inc.
Viatris Inc.
Hold
$13.6B
-30.35%
224.4
-4.24%
Catalent, Inc.
Catalent, Inc.
Hold
$11.0B
25.05%
211.02
-23.81%

Institutional Holdings

    Company Information

    kamada ltd. is focused on plasma-derived protein therapeutics for orphan indications, and has a commercial product portfolio and a robust late-stage product pipeline. the company uses its proprietary platform technology and know-how for the extraction and purification of proteins from human plasma to produce alpha-1 antitrypsin (aat) in a highly-purified, liquid form, as well as other plasma-derived proteins. aat is a protein derived from human plasma with known and newly-discovered therapeutic roles given its immunomodulatory, anti-inflammatory, tissue-protective and antimicrobial properties. the company’s flagship product is glassia®, the first and only liquid, ready-to-use, intravenous plasma-derived aat product approved by the u.s. food and drug administration. kamada markets glassia in the u.s. through a strategic partnership with baxter international. in addition to glassia, kamada has a product line of nine other pharmaceutical products that are marketed through distributor

    Organization
    Kamada Ltd
    Employees
    378
    CEO
    Mr. Amir London
    Industry
    Health Technology

    Discover More

    FAQs